DOCSLIB.ORG

Delivery of an Enzyme-IGFII Fusion Protein to the Mouse Brain Is Therapeutic for Mucopolysaccharidosis Type IIIB

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Delivery of an Enzyme-IGFII Fusion Protein to the Mouse Brain Is Therapeutic for Mucopolysaccharidosis Type IIIB Delivery of an enzyme-IGFII fusion protein to the mouse brain is therapeutic for mucopolysaccharidosis type IIIB Shih-hsin Kana, Mika Aoyagi-Scharberb,1, Steven Q. Lea, Jon Vinceletteb, Kazuhiro Ohmic, Sherry Bullensb, Daniel J. Wendtd, Terri M. Christiansonb, Pascale M. N. Tigerb, Jillian R. Brownb, Roger Lawrenceb, Bryan K. Yipb, John Holtzingerb, Anil Bagrib, Danielle Crippen-Harmonb, Kristen N. Vondraka, Zhi Chend, Chuck M. Hagued, Josh C. Woloszynekb, Diana S. Cheungb, Katherine A. Websterb, Evan G. Adintorib, Melanie J. Lob, Wesley Wongb, Paul A. Fitzpatrickb, Jonathan H. LeBowitzb, Brett E. Crawfordb, Stuart Buntingb, Patricia I. Dicksona,1, and Elizabeth F. Neufeldc,1 aDepartment of Pediatrics, Los Angeles Biomedical Research Institute at Harbor–UCLA Medical Center, Torrance, CA 90502; bResearch and Drug Discovery and dAnalytical Chemistry, BioMarin Pharmaceutical, Inc., Novato, CA 94949; and cDepartment of Biological Chemistry, David Geffen School of Medicine, University of California, Los Angeles, CA 90095 Contributed by Elizabeth F. Neufeld, August 29, 2014 (sent for review August 3, 2014; reviewed by Roscoe O. Brady and William S. Sly) Mucopolysaccharidosis type IIIB (MPS IIIB, Sanfilippo syndrome (NAGLU), there is an additional difficulty in that, in contrast to type B) is a lysosomal storage disease characterized by profound in- most other soluble lysosomal enzymes, recombinant NAGLU tellectual disability, dementia, and a lifespan of about two decades. produced in Chinese hamster ovary (CHO) cells contains little or Thecauseismutationinthegeneencodingα–N-acetylglucosaminidase no mannose 6-phosphate (Man6-P) (9–11), the signal for receptor- (NAGLU), deficiency of NAGLU, and accumulation of heparan sulfate. mediated endocytosis and targeting to lysosomes (12, 13). The Impediments to enzyme replacement therapy are the absence of man- reason for the lack of the Man6-P modification is not understood – nose 6-phosphate on recombinant human NAGLU and the blood and appears to apply only to the recombinant enzyme, as human brain barrier. To overcome the first impediment, a fusion protein of urinary NAGLU (14) and endogenous NAGLU made by CHO recombinant NAGLU and a fragment of insulin-like growth factor II cells (9) contain Man6-P. (IGFII) was prepared for endocytosis by the mannose 6-phosphate/ The lack of Man6-P on the enzyme can be overcome by taking IGFII receptor. To bypass the blood–brain barrier, the fusion protein (“enzyme”) in artificial cerebrospinal fluid (“vehicle”) was adminis- advantage of the ability of the cation-independent Man6-P re- tered intracerebroventricularly to the brain of adult MPS IIIB mice, ceptor to bind insulin-like growth factor II (IGFII) at a site – four times over 2 wk. The brains were analyzed 1–28 d later and distinct from the Man6-P binding sites (15 19). Fusion proteins compared with brains of MPS IIIB mice that received vehicle alone consisting of a fragment of IGFII linked to a lysosomal enzyme or control (heterozygous) mice that received vehicle. There was marked uptake of the administered enzyme in many parts of the Significance brain, where it persisted with a half-life of approximately 10 d. Hep- aran sulfate, and especially disease-specific heparan sulfate, was Mucopolysaccharidosis type IIIB (MPS IIIB) is a devastating and reduced to control level. A number of secondary accumulations currently untreatable disease affecting mainly the brain. The in neurons [β-hexosaminidase, LAMP1(lysosome-associated mem- cause is lack of the lysosomal enzyme, α–N-acetylglucosami- brane protein 1), SCMAS (subunit c of mitochondrial ATP synthase), nidase (NAGLU), and storage of heparan sulfate. Using a mouse glypican 5, β-amyloid, P-tau] were reduced almost to control level. model of MPS IIIB, we administered a modified NAGLU by in- CD68, a microglial protein, was reduced halfway. A large amount of jection into the left ventricle of the brain, bypassing the blood– enzyme also appeared in liver cells, where it reduced heparan sulfate brain barrier. The modification consisted of a fragment of IGFII, and β-hexosaminidase accumulation to control levels. These results which allows receptor-mediated uptake and delivery to lyso- suggest the feasibility of enzyme replacement therapy for MPS IIIB. somes. The modified enzyme was taken up avidly by cells in both brain and liver, where it reduced pathological accumula- ucopolysaccharidosis type III (MPS III, Sanfilippo syn- tion of heparan sulfate and other metabolites to normal or Mdrome) is a heritable lysosomal disorder of heparan sulfate near-normal levels. The results suggest the possibility of treat- degradation, divided into four types (A–D), depending on the ment for MPS IIIB. enzyme deficiency (1, 2). All four MPS III types are characterized Author contributions: M.A.-S., J.V., S. Bullens, D.J.W., T.M.C., P.A.F., J.H.L., B.E.C., S. Bunting, by severe neurologic problems and relatively mild somatic ones. P.I.D., and E.F.N. designed research; S.-h.K., S.Q.L., J.V., K.O., D.J.W., T.M.C., P.M.N.T., J.R.B., Profound intellectual disability that progresses to dementia, be- R.L., B.K.Y., J.H., A.B., D.C.-H., K.N.V., Z.C., C.M.H., J.C.W., D.S.C., K.A.W., E.G.A., M.J.L., and havioral disturbances, and death in the second or third decade W.W. performed research; S.-h.K., M.A.-S., S.Q.L., K.O., S. Bullens, D.J.W., T.M.C., J.R.B., R.L., bring untold suffering to the MPS III patients and their families. B.K.Y., J.H., A.B., D.C.-H., Z.C., C.M.H., J.C.W., K.A.W., E.G.A., B.E.C., P.I.D., and E.F.N. ana- lyzed data; and S.-h.K., M.A.-S., and E.F.N. wrote the paper. Despite the dire need, treatment for the MPS III disorders has Reviewers: R.O.B., National Institute of Neurological Disorders and Stroke; and W.S.S., lagged behind other MPS diseases. Hematopoietic stem cell trans- Saint Louis University School of Medicine. plantation, an effective procedure for MPS I patients with CNS in- Conflict of interest statement: M.A.-S., J.V., S. Bullens., D.J.W., T.M.C., P.M.N.T., J.R.B., R.L., volvement (3), is not effective for MPS III (4). Enzyme replacement B.K.Y., J.H., A.B., D.C.-H., Z.C., C.M.H., J.C.W., D.S.C., K.A.W., E.G.A., M.J.L., W.W., P.A.F., therapy has been available for some years for several MPS with J.H.L., B.E.C., and S. Bunting are employees of BioMarin Pharmaceutical, Inc., which is developing a commercial treatment for mucopolysaccharidosis type IIIB. E.F.N. is principal extensive somatic involvement [MPS I (5, 6), II (7), and VI (8)], or is investigator of a sponsored research agreement with BioMarin Pharmaceutical, Inc. newly approved (MPS IVA), or in clinical trial (MPS VII). However, Freely available online through the PNAS open access option. development of enzyme replacement for MPS III did not seem 1To whom correspondence may be addressed. Email: [email protected], promising because access to therapeutic enzyme to brain paren- [email protected], or [email protected]. – chyma would be limited by the blood brain barrier. With respect to This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10. MPS IIIB, a deficiency of α–N-acetylglucosaminidase, EC 3.2.1.50) 1073/pnas.1416660111/-/DCSupplemental. 14870–14875 | PNAS | October 14, 2014 | vol. 111 | no. 41 www.pnas.org/cgi/doi/10.1073/pnas.1416660111 Downloaded by guest on October 1, 2021 with no Man6-P have been made for β-glucuronidase (20), α-glu- cosidase (21), and NAGLU (11), and shown to have enzymatic activity similar to that of the original lysosomal enzyme and to be taken up by cultured cells in a manner that is dependent on IGFII and independent of Man6-P. In addition, the β-glucuronidase– and α-glucosidase–IGFII fusion proteins, administered i.v. to de- ficient mice, were found to be taken up by major somatic organs and muscles, respectively, in which they functioned to reduce storage and pathology (20, 21). On the basis of these promising earlier studies, we treated the brain of the MPS IIIB mouse by administering a NAGLU–IGFII fusion protein directly into the left cerebral ventricle, bypassing the blood–brain barrier. The modified enzyme was endocytosed mainly into neurons, where it Fig. 2. Uptake of NAGLU–IGFII by MPS IIIB mouse brain after intra- functioned to reduce the level of stored heparan sulfate and of cerebroventricular administration of NAGLU–IGFII. (A) NAGLU taken up, other accumulated substances to a normal or near-normal level. It measured as NAGLU catalytic activity in homogenates of slice 1. Measure- also spread to the liver, where it was endocytosed into vascular cells ments are in units per milligram of protein, expressed as mean ± SD. The and hepatocytes and eliminated storage of heparan sulfate. The brains were taken at the times indicated (in days from the last injection) from – results suggest that the combined use of the IGFII signal for en- mice treated with NAGLU IGFII (ENZ) or vehicle (VEH). The number of mouse docytosis with administration directly into the brain may overcome brains analyzed at each time point, going from left to right, was 7, 4, 8, 4, 4, 4, and 8. (B) Immunohistochemical staining for NAGLU in cortex (slice 2) and in the major obstacles to enzyme replacement therapy for MPS IIIB. CA3 layer of the hippocampus (slice 4), in the mutant mice treated with ve- A preliminary account of this work has been presented in hicle or with enzyme, as indicated.
Load more

Recommended publications
  • Bacteria Belonging to Pseudomonas Typographi Sp. Nov. from the Bark Beetle Ips Typographus Have Genomic Potential to Aid in the Host Ecology
    insects Article Bacteria Belonging to Pseudomonas typographi sp. nov. from the Bark Beetle Ips typographus Have Genomic Potential to Aid in the Host Ecology Ezequiel Peral-Aranega 1,2 , Zaki Saati-Santamaría 1,2 , Miroslav Kolaˇrik 3,4, Raúl Rivas 1,2,5 and Paula García-Fraile 1,2,4,5,* 1 Microbiology and Genetics Department, University of Salamanca, 37007 Salamanca, Spain; [email protected] (E.P.-A.); [email protected] (Z.S.-S.); [email protected] (R.R.) 2 Spanish-Portuguese Institute for Agricultural Research (CIALE), 37185 Salamanca, Spain 3 Department of Botany, Faculty of Science, Charles University, Benátská 2, 128 01 Prague, Czech Republic; [email protected] 4 Laboratory of Fungal Genetics and Metabolism, Institute of Microbiology of the Academy of Sciences of the Czech Republic, 142 20 Prague, Czech Republic 5 Associated Research Unit of Plant-Microorganism Interaction, University of Salamanca-IRNASA-CSIC, 37008 Salamanca, Spain * Correspondence: [email protected] Received: 4 July 2020; Accepted: 1 September 2020; Published: 3 September 2020 Simple Summary: European Bark Beetle (Ips typographus) is a pest that affects dead and weakened spruce trees. Under certain environmental conditions, it has massive outbreaks, resulting in attacks of healthy trees, becoming a forest pest. It has been proposed that the bark beetle’s microbiome plays a key role in the insect’s ecology, providing nutrients, inhibiting pathogens, and degrading tree defense compounds, among other probable traits. During a study of bacterial associates from I. typographus, we isolated three strains identified as Pseudomonas from different beetle life stages. In this work, we aimed to reveal the taxonomic status of these bacterial strains and to sequence and annotate their genomes to mine possible traits related to a role within the bark beetle holobiont.
    [Show full text]
  • Epidemiology of Mucopolysaccharidoses Update
    diagnostics Review Epidemiology of Mucopolysaccharidoses Update Betul Celik 1,2 , Saori C. Tomatsu 2 , Shunji Tomatsu 1 and Shaukat A. Khan 1,* 1 Nemours/Alfred I. duPont Hospital for Children, Wilmington, DE 19803, USA; [email protected] (B.C.); [email protected] (S.T.) 2 Department of Biological Sciences, University of Delaware, Newark, DE 19716, USA; [email protected] * Correspondence: [email protected]; Tel.: +302-298-7335; Fax: +302-651-6888 Abstract: Mucopolysaccharidoses (MPS) are a group of lysosomal storage disorders caused by a lysosomal enzyme deficiency or malfunction, which leads to the accumulation of glycosaminoglycans in tissues and organs. If not treated at an early stage, patients have various health problems, affecting their quality of life and life-span. Two therapeutic options for MPS are widely used in practice: enzyme replacement therapy and hematopoietic stem cell transplantation. However, early diagnosis of MPS is crucial, as treatment may be too late to reverse or ameliorate the disease progress. It has been noted that the prevalence of MPS and each subtype varies based on geographic regions and/or ethnic background. Each type of MPS is caused by a wide range of the mutational spectrum, mainly missense mutations. Some mutations were derived from the common founder effect. In the previous study, Khan et al. 2018 have reported the epidemiology of MPS from 22 countries and 16 regions. In this study, we aimed to update the prevalence of MPS across the world. We have collected and investigated 189 publications related to the prevalence of MPS via PubMed as of December 2020. In total, data from 33 countries and 23 regions were compiled and analyzed.
    [Show full text]
  • Uptake of -(L)-Iduronidase Produced by Retrovirally Transduced
    Gene Therapy (1997) 4, 63–75 1997 Stockton Press All rights reserved 0969-7128/97 $12.00 Uptake of a-(L)-iduronidase produced by retrovirally transduced fibroblasts into neuronal and glial cells in vitro K Stewart1, OA Brown1, AE Morelli1, LJ Fairbairn2, LS Lashford2,3, A Cooper4, CE Hatton4, TM Dexter2, MG Castro1 and PR Lowenstein1 1Molecular Medicine Unit, Department of Medicine, University of Manchester School of Medicine; 2CRC Department of Experimental Haematology, Paterson Institute for Cancer Research, Christie Hospital NHS Trust, Manchester; 3Academic Unit of Pediatric Oncology, Christie Hospital NHS Trust, Manchester; and 4Willink Biochemical Genetics Unit, Royal Manchester Children’s Hospital, Manchester, UK The uptake of recombinant a-(L)-iduronidase into glial and higher in actively dividing or immature brain cells. Conse- neuronal cells, produced by retrovirally transduced NIH3T3 quently, (1) neuronal metabolism ought to be capable of fibroblasts, was studied. We demonstrate that: (1) neuronal cross correction by enzyme provided by genetically engine- and glial cells take up a-(L)-iduronidase released into the ered and transplanted cells provided by bone marrow medium by retrovirally transduced fibroblasts expressing transplantation (BMT); (2) that BMT could have a more high levels of a-(L)-iduronidase; (2) both glial and neuronal beneficial effect on neurological function if performed as cells express the cation independent mannose-6-phos- early as possible; and (3) given that the uptake mechanism phate receptor responsible for lysosomal enzyme uptake; of glial cells has a higher capacity, it might be easier to and (3) uptake of the lysosomal enzyme can be blocked target diseases like the leukodystrophies in which lysoso- by excess free mannose-6-phosphate, but not glucose-6- mal enzymes are needed in glial cells, compared to dis- phosphate.
    [Show full text]
  • Mini-Review on “Molecular Diagnosis of 65 Families With
    Mashima R, Okuyama T. J Rare Dis Res Treat. (2016) 2(1): 43-46 Journal of www.rarediseasesjournal.com Rare Diseases Research & Treatment Mini-Review Open Access Mini-review on “Molecular diagnosis of 65 families with mucopoly- saccharidosis type II (Hunter syndrome) characterized by 16 novel mutations in the IDS gene: Genetic, pathological, and structural stud- ies on iduronate-2-sulfatase.” Ryuichi Mashima1* and Torayuki Okuyama1,2 1Department of Clinical Laboratory Medicine, National Center for Child Health and Development, 2-10-1 Okura, Setagaya-ku, Tokyo 157-8535, Japan 2Center for Lysosomal Storage Disorders, National Center for Child Health and Development, 2-10-1 Okura, Setagaya-ku, Tokyo 157-8535, Japan ABSTRACT Article Info Article Notes Mucopolysaccharidosis type II (MPS II; Hunter syndrome; OMIM #309900) Received: November 29, 2016 is an X-linked congenital disorder characterized by an accumulation of Accepted: December 28, 2016 glycosaminoglycans in the body. Accumulating evidence has suggested that the prevalence of the severe type of MPS II is almost 70%. In addition, novel *Correspondence: mutations that are relevant to MPS II pathogenesis are being increasingly Ryuichi Mashima, Department of Clinical Laboratory Medicine, National Center for Child Health and Development, 2-10- discovered, so the databases of genetic data regarding pathogenic mutations 1 Okura, Setagaya-ku, Tokyo 157-8535, Japan, E-mail: have been growing. We have recently reported a collection of 16 novel [email protected] pathogenic mutations of the iduronate-2-sulfatase (IDS) gene in 65 families with MPS II in a Japanese population1. We also proposed that a homology- © 2016 Ryuichi Mashima.
    [Show full text]
  • Functional Characterization of Carbohydrate-Active Enzymes from Marine Bacteria
    Functional characterization of carbohydrate-active enzymes from marine bacteria I n a u g u r a l d i s s e r t a t i o n zur Erlangung des akademischen Grades eines Doktors der Naturwissenschaften (Dr. rer. nat.) der Mathematisch-Naturwissenschaftlichen Fakultät der Universität Greifswald vorgelegt von Marcus Bäumgen Greifswald, 28.02.2020 Dekan: Prof. Dr. Werner Weitschies 1. Gutachter: Prof. Dr. Uwe T. Bornscheuer 2. Gutachter: Prof. Dr. Harry Brumer Tag der Promotion: 24.06.2020 II III Wissenschaft ist das Werkzeug, welches es uns ermöglicht, das große Puzzel der Natur und des Lebens zu lösen. IV Auch wenn wir den Weg des Wissens und der Weisheit niemals bis zum Ende beschreiten können, so ist doch jeder Schritt, den wir tun, ein Schritt in eine bessere Welt. V Content Abbreviations ..................................................................................................................... IX 1. Introduction ..................................................................................................................... 1 1.1 The marine carbon cycle .............................................................................................. 1 1.1.1 Algal blooms .......................................................................................................... 1 1.1.2 The marine carbohydrates ulvan and xylan ........................................................... 2 1.1.3 Marine polysaccharide utilization ........................................................................... 4 1.2 Carbohydrate-active enzymes
    [Show full text]
  • United States Patent (19) 11 Patent Number: 5,981,835 Austin-Phillips Et Al
    USOO598.1835A United States Patent (19) 11 Patent Number: 5,981,835 Austin-Phillips et al. (45) Date of Patent: Nov. 9, 1999 54) TRANSGENIC PLANTS AS AN Brown and Atanassov (1985), Role of genetic background in ALTERNATIVE SOURCE OF Somatic embryogenesis in Medicago. Plant Cell Tissue LIGNOCELLULOSC-DEGRADING Organ Culture 4:107-114. ENZYMES Carrer et al. (1993), Kanamycin resistance as a Selectable marker for plastid transformation in tobacco. Mol. Gen. 75 Inventors: Sandra Austin-Phillips; Richard R. Genet. 241:49-56. Burgess, both of Madison; Thomas L. Castillo et al. (1994), Rapid production of fertile transgenic German, Hollandale; Thomas plants of Rye. Bio/Technology 12:1366–1371. Ziegelhoffer, Madison, all of Wis. Comai et al. (1990), Novel and useful properties of a chimeric plant promoter combining CaMV 35S and MAS 73 Assignee: Wisconsin Alumni Research elements. Plant Mol. Biol. 15:373-381. Foundation, Madison, Wis. Coughlan, M.P. (1988), Staining Techniques for the Detec tion of the Individual Components of Cellulolytic Enzyme 21 Appl. No.: 08/883,495 Systems. Methods in Enzymology 160:135-144. de Castro Silva Filho et al. (1996), Mitochondrial and 22 Filed: Jun. 26, 1997 chloroplast targeting Sequences in tandem modify protein import specificity in plant organelles. Plant Mol. Biol. Related U.S. Application Data 30:769-78O. 60 Provisional application No. 60/028,718, Oct. 17, 1996. Divne et al. (1994), The three-dimensional crystal structure 51 Int. Cl. ............................. C12N 15/82; C12N 5/04; of the catalytic core of cellobiohydrolase I from Tricho AO1H 5/00 derma reesei. Science 265:524-528.
    [Show full text]
  • Alpha-L-Iduronidase Transduced Mesenchymal Stem Cells As A
    ALPHA-L-IDURONIDASE TRANSDUCED MESENCHYMAL STEM CELLS AS A THERAPY FOR THE TREATMENT OF CNS DEGENERATION IN MUCOPOLYSACCHARIDOSIS TYPE I MICE Matilda Jackson BMSc, BSc (Hons) Matrix Biology Unit SA Pathology Thesis submitted for the degree of Doctor of Philosophy in Discipline of Genetics School of Molecular and Biomedical Sciences Faculty of Science The University of Adelaide Table of contents Abstract........................................................................................................... vii Declaration....................................................................................................... ix Acknowledgements ........................................................................................... x Abbreviations .................................................................................................. xi Chapter One: Introduction .............................................................................. 1 1.0 Overview .................................................................................................................... 2 1.1 The Mucopolysaccharidoses .................................................................................... 3 1.1.1 Mucopolysaccharidoses type I......................................................................................... 5 1.1.2 Central Nervous System (CNS) pathology ...................................................................... 7 1.1.3 Bone pathology ..............................................................................................................
    [Show full text]
  • Enzyme Replacement Therapy Srx-0019 Policy Type ☒ Medical ☐ Administrative ☐ Payment
    MEDICAL POLICY STATEMENT Original Effective Date Next Annual Review Date Last Review / Revision Date 06/15/2011 03/15/2017 10/04/2016 Policy Name Policy Number Enzyme Replacement Therapy SRx-0019 Policy Type ☒ Medical ☐ Administrative ☐ Payment Medical Policy Statements prepared by CSMG Co. and its affiliates (including CareSource) are derived from literature based on and supported by clinical guidelines, nationally recognized utilization and technology assessment guidelines, other medical management industry standards, and published MCO clinical policy guidelines. Medically necessary services include, but are not limited to, those health care services or supplies that are proper and necessary for the diagnosis or treatment of disease, illness, or injury and without which the patient can be expected to suffer prolonged, increased or new morbidity, impairment of function, dysfunction of a body organ or part, or significant pain and discomfort. These services meet the standards of good medical practice in the local area, are the lowest cost alternative, and are not provided mainly for the convenience of the member or provider. Medically necessary services also include those services defined in any Evidence of Coverage documents, Medical Policy Statements, Provider Manuals, Member Handbooks, and/or other policies and procedures. Medical Policy Statements prepared by CSMG Co. and its affiliates (including CareSource) do not ensure an authorization or payment of services. Please refer to the plan contract (often referred to as the Evidence of Coverage) for the service(s) referenced in the Medical Policy Statement. If there is a conflict between the Medical Policy Statement and the plan contract (i.e., Evidence of Coverage), then the plan contract (i.e., Evidence of Coverage) will be the controlling document used to make the determination.
    [Show full text]
  • Beta-Galactosidase Deficiency: Beta-Galactosidase Activity, Leukocytes Test Code: LO Turnaround Time: 7 Days - 10 Days CPT Codes: 82657 X1
    2460 Mountain Industrial Boulevard | Tucker, Georgia 30084 Phone: 470-378-2200 or 855-831-7447 | Fax: 470-378-2250 eglgenetics.com Beta-Galactosidase Deficiency: Beta-Galactosidase Activity, Leukocytes Test Code: LO Turnaround time: 7 days - 10 days CPT Codes: 82657 x1 Condition Description Beta-galactosidase deficiency is associated with three distinct autosomal recessive lysosomal storage disorders: GM1 gangliosidosis (GM1), mucopolysaccharidosis type IVB (MPS IVB), and galactosialidosis. GM1 and MPS IVB are referred to as GLB1-related disorders as they are the result of biallelic mutations in GLB1. Galactosialidosis is caused by mutations in CTSA (cathepsin A) and results in decreased activity of beta-galactosidase and neuraminidase. Deficiency of beta-galactosidase leads to the accumulation of sphingolipid intermediates in lysosomes of neuronal tissue, resulting in the CNS deterioration typical of GM1. Deficiency of this enzyme also leads to accumulation of the glycosaminoglycan (GAG) keratan sulfate in cartilage which is suspected to cause the skeletal findings associated with MPS IVB. Patients with GM1 have a characteristic abnormal pattern of oligosaccharide elevations in urine detectable by TLC and MALDI-TOF mass spectrometry. Patients with MPS IVB have detectable bands of keratan sulfate by GAG analysis with TLC. Keratan sulfate is also present in MPS IVA and the clinical presentation of MPS IVB is not distinguishable from that of MPS IVA. Patients with galactosialidosis also have characteristic oligosaccharide elevations and decreased neuraminidase 1 enzyme levels. Neuraminidase testing and molecular analysis of CTSA is recommended to confirm a diagnosis of galactosialidosis. Determination of beta-galactosidase levels is not recommended for carrier detection. GM1 gangliosidosis has been classified into three major clinical forms according to the age of onset and severity of symptoms: type I (infantile), type II (late infantile/juvenile) and type III (adult).
    [Show full text]
  • Mucopolysaccharidosis Type II: One Hundred Years of Research, Diagnosis, and Treatment
    International Journal of Molecular Sciences Review Mucopolysaccharidosis Type II: One Hundred Years of Research, Diagnosis, and Treatment Francesca D’Avanzo 1,2 , Laura Rigon 2,3 , Alessandra Zanetti 1,2 and Rosella Tomanin 1,2,* 1 Laboratory of Diagnosis and Therapy of Lysosomal Disorders, Department of Women’s and Children ‘s Health, University of Padova, Via Giustiniani 3, 35128 Padova, Italy; [email protected] (F.D.); [email protected] (A.Z.) 2 Fondazione Istituto di Ricerca Pediatrica “Città della Speranza”, Corso Stati Uniti 4, 35127 Padova, Italy; [email protected] 3 Molecular Developmental Biology, Life & Medical Science Institute (LIMES), University of Bonn, 53115 Bonn, Germany * Correspondence: [email protected] Received: 17 January 2020; Accepted: 11 February 2020; Published: 13 February 2020 Abstract: Mucopolysaccharidosis type II (MPS II, Hunter syndrome) was first described by Dr. Charles Hunter in 1917. Since then, about one hundred years have passed and Hunter syndrome, although at first neglected for a few decades and afterwards mistaken for a long time for the similar disorder Hurler syndrome, has been clearly distinguished as a specific disease since 1978, when the distinct genetic causes of the two disorders were finally identified. MPS II is a rare genetic disorder, recently described as presenting an incidence rate ranging from 0.38 to 1.09 per 100,000 live male births, and it is the only X-linked-inherited mucopolysaccharidosis. The complex disease is due to a deficit of the lysosomal hydrolase iduronate 2-sulphatase, which is a crucial enzyme in the stepwise degradation of heparan and dermatan sulphate.
    [Show full text]
  • Tepzz¥5Z5 8 a T
    (19) TZZ¥Z___T (11) EP 3 505 181 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 03.07.2019 Bulletin 2019/27 A61K 38/46 (2006.01) C12N 9/16 (2006.01) (21) Application number: 18248241.4 (22) Date of filing: 28.12.2018 (84) Designated Contracting States: (72) Inventors: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB • DICKSON, Patricia GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO Torrance, CA California 90502 (US) PL PT RO RS SE SI SK SM TR • CHOU, Tsui-Fen Designated Extension States: Torrance, CA California 90502 (US) BA ME • EKINS, Sean Designated Validation States: Brooklyn, NY New York 11215 (US) KH MA MD TN • KAN, Shih-Hsin Torrance, CA California 90502 (US) (30) Priority: 28.12.2017 US 201762611472 P • LE, Steven 05.04.2018 US 201815946505 Torrance, CA California 90502 (US) • MOEN, Derek R. (71) Applicants: Torrance, CA California 90502 (US) • Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (74) Representative: J A Kemp Torrance, CA 90502 (US) 14 South Square • Phoenix Nest Inc. Gray’s Inn Brooklyn NY 11215 (US) London WC1R 5JJ (GB) (54) PREPARATION OF ENZYME REPLACEMENT THERAPY FOR MUCOPOLYSACCHARIDOSIS IIID (57) The present disclosure relates to compositions for use in a method of treating Sanfilippo syndrome (also known as Sanfilippo disease type D, Sanfilippo D, mu- copolysaccharidosis type IIID, MPS IIID). The method can entail injecting to the spinal fluid of a MPS IIID patient an effective amount of a composition comprising a re- combinant human acetylglucosamine-6-sulfatase (GNS) protein comprising the amino acid sequence of SEQ ID NO: 1 or an amino acid sequence having at least 90% sequence identity to SEQ ID NO: 1 and having the en- zymatic activity of the human GNS protein.
    [Show full text]
  • Association of Gene Ontology Categories with Decay Rate for Hepg2 Experiments These Tables Show Details for All Gene Ontology Categories
    Supplementary Table 1: Association of Gene Ontology Categories with Decay Rate for HepG2 Experiments These tables show details for all Gene Ontology categories. Inferences for manual classification scheme shown at the bottom. Those categories used in Figure 1A are highlighted in bold. Standard Deviations are shown in parentheses. P-values less than 1E-20 are indicated with a "0". Rate r (hour^-1) Half-life < 2hr. Decay % GO Number Category Name Probe Sets Group Non-Group Distribution p-value In-Group Non-Group Representation p-value GO:0006350 transcription 1523 0.221 (0.009) 0.127 (0.002) FASTER 0 13.1 (0.4) 4.5 (0.1) OVER 0 GO:0006351 transcription, DNA-dependent 1498 0.220 (0.009) 0.127 (0.002) FASTER 0 13.0 (0.4) 4.5 (0.1) OVER 0 GO:0006355 regulation of transcription, DNA-dependent 1163 0.230 (0.011) 0.128 (0.002) FASTER 5.00E-21 14.2 (0.5) 4.6 (0.1) OVER 0 GO:0006366 transcription from Pol II promoter 845 0.225 (0.012) 0.130 (0.002) FASTER 1.88E-14 13.0 (0.5) 4.8 (0.1) OVER 0 GO:0006139 nucleobase, nucleoside, nucleotide and nucleic acid metabolism3004 0.173 (0.006) 0.127 (0.002) FASTER 1.28E-12 8.4 (0.2) 4.5 (0.1) OVER 0 GO:0006357 regulation of transcription from Pol II promoter 487 0.231 (0.016) 0.132 (0.002) FASTER 6.05E-10 13.5 (0.6) 4.9 (0.1) OVER 0 GO:0008283 cell proliferation 625 0.189 (0.014) 0.132 (0.002) FASTER 1.95E-05 10.1 (0.6) 5.0 (0.1) OVER 1.50E-20 GO:0006513 monoubiquitination 36 0.305 (0.049) 0.134 (0.002) FASTER 2.69E-04 25.4 (4.4) 5.1 (0.1) OVER 2.04E-06 GO:0007050 cell cycle arrest 57 0.311 (0.054) 0.133 (0.002)
    [Show full text]